These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 12502967)

  • 1. The diagnostic value of hepatocyte paraffin antibody 1 in differentiating hepatocellular neoplasms from nonhepatic tumors: a review.
    Lamps LW; Folpe AL
    Adv Anat Pathol; 2003 Jan; 10(1):39-43. PubMed ID: 12502967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The utility of hepatocyte paraffin 1 antibody in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma and metastatic carcinoma.
    Shiran MS; Isa MR; Sherina MS; Rampal L; Hairuszah I; Sabariah AR
    Malays J Pathol; 2006 Dec; 28(2):87-92. PubMed ID: 18376797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bile salt export pump: a sensitive and specific immunohistochemical marker of hepatocellular carcinoma.
    Lagana SM; Salomao M; Remotti HE; Knisely AS; Moreira RK
    Histopathology; 2015 Mar; 66(4):598-602. PubMed ID: 25378077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SALL4 represents fetal gut differentiation of gastric cancer, and is diagnostically useful in distinguishing hepatoid gastric carcinoma from hepatocellular carcinoma.
    Ushiku T; Shinozaki A; Shibahara J; Iwasaki Y; Tateishi Y; Funata N; Fukayama M
    Am J Surg Pathol; 2010 Apr; 34(4):533-40. PubMed ID: 20182341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High mobility group A1 is expressed in metastatic adenocarcinoma to the liver and intrahepatic cholangiocarcinoma, but not in hepatocellular carcinoma: its potential use in the diagnosis of liver neoplasms.
    Abe N; Watanabe T; Izumisato Y; Suzuki Y; Masaki T; Mori T; Sugiyama M; Fusco A; Atomi Y
    J Gastroenterol; 2003; 38(12):1144-9. PubMed ID: 14714251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The expression of arginase-1, keratin (K) 8 and K18 in combined hepatocellular-cholangiocarcinoma, subtypes with stem-cell features, intermediate-cell type.
    Akiba J; Nakashima O; Hattori S; Naito Y; Kusano H; Kondo R; Nakayama M; Tanikawa K; Todoroki K; Umeno Y; Nakamura K; Sanada S; Yamaguchi R; Ogasawara S; Yano H
    J Clin Pathol; 2016 Oct; 69(10):846-51. PubMed ID: 26969740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of immunohistochemical markers for differential diagnosis of hepatocellular carcinoma from intrahepatic cholangiocarcinoma].
    Dong H; Cong WL; Zhu ZZ; Wang B; Xian ZH; Yu H
    Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):702-5. PubMed ID: 19173916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MOC31 immunoreactivity in primary and metastatic carcinoma of the liver. Report of findings and review of other utilized markers.
    Proca DM; Niemann TH; Porcell AI; DeYoung BR
    Appl Immunohistochem Mol Morphol; 2000 Jun; 8(2):120-5. PubMed ID: 10937059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The diagnostic value of arginase-1 immunostaining in differentiating hepatocellular carcinoma from metastatic carcinoma and cholangiocarcinoma as compared to HepPar-1.
    Radwan NA; Ahmed NS
    Diagn Pathol; 2012 Oct; 7():149. PubMed ID: 23111165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The alphavbeta6 integrin is a highly specific immunohistochemical marker for cholangiocarcinoma.
    Patsenker E; Wilkens L; Banz V; Osterreicher CH; Weimann R; Eisele S; Keogh A; Stroka D; Zimmermann A; Stickel F
    J Hepatol; 2010 Mar; 52(3):362-9. PubMed ID: 20137822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative analysis of immunohistochemical markers for differential diagnosis of hepatocelluar carcinoma and cholangiocarcinoma.
    Ryu HS; Lee K; Shin E; Kim SH; Jing J; Jung HY; Lee H; Jang JJ
    Tumori; 2012; 98(4):478-84. PubMed ID: 23052165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on Ancillary Testing in the Evaluation of High-Grade Liver Tumors.
    Koehne de Gonzalez A; Lagana SM
    Surg Pathol Clin; 2018 Jun; 11(2):367-375. PubMed ID: 29751880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [In vivo proton magnetic resonance spectroscopy of hepatocellular carcinoma and cholangiocarcinoma].
    Dong AS; Tian JM; Lu JP; Zuo CJ; Wang L; Wang J
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Apr; 31(2):151-4. PubMed ID: 19507591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A case of AFP-producing cholangiocarcinoma with difficulty in differential diagnosis from hepatocellular carcinoma].
    Omori J; Niimi A; Furuichi Y; Takeuchi E; Ishikawa T; Yanagisawa A; Ogihara S; Tsuchiya M; Misaka R; Shigemoto M; Kurihara T; Maeda A; Yamashita K; Aratake T; Kameoka S; Nishikawa T
    Nihon Shokakibyo Gakkai Zasshi; 2004 Oct; 101(10):1106-11. PubMed ID: 15529784
    [No Abstract]   [Full Text] [Related]  

  • 15. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma.
    Yamauchi N; Watanabe A; Hishinuma M; Ohashi K; Midorikawa Y; Morishita Y; Niki T; Shibahara J; Mori M; Makuuchi M; Hippo Y; Kodama T; Iwanari H; Aburatani H; Fukayama M
    Mod Pathol; 2005 Dec; 18(12):1591-8. PubMed ID: 15920546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SMARCB1/INI1 Is Diagnostically Useful in Distinguishing α-Fetoprotein-producing Gastric Carcinoma from Hepatocellular Carcinoma.
    Mochizuki K; Kawai M; Odate T; Tahara I; Inoue T; Kasai K; Nakazawa T; Kondo T
    Anticancer Res; 2018 Dec; 38(12):6865-6868. PubMed ID: 30504402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocyte paraffin 1 antibody does not distinguish primary ovarian tumors with hepatoid differentiation from metastatic hepatocellular carcinoma.
    Pitman MB; Triratanachat S; Young RH; Oliva E
    Int J Gynecol Pathol; 2004 Jan; 23(1):58-64. PubMed ID: 14668552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Das-1 immunostain is useful for discriminating metastatic colon adenocarcinoma from cholangiocarcinoma and hepatocellular carcinoma.
    Zimmerman RL; Das KM; Fogt F; Burke M; Murakata LA
    Oncol Rep; 2002; 9(6):1369-72. PubMed ID: 12375050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A mixed hepatocellular carcinoma and cholangiocarcinoma: dual expression of biliary-type cytokeratin and hepatocyte specific marker.
    Tanaka S; Hirohashi K; Uenishi T; Yamamoto T; Hamba H; Kubo S; Tanaka H; Shuto T; Ogawa M; Kinoshita H
    Hepatogastroenterology; 2004; 51(57):839-41. PubMed ID: 15143930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocyte antigen as a marker of hepatocellular carcinoma: an immunohistochemical comparison to carcinoembryonic antigen, CD10, and alpha-fetoprotein.
    Chu PG; Ishizawa S; Wu E; Weiss LM
    Am J Surg Pathol; 2002 Aug; 26(8):978-88. PubMed ID: 12170084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.